Reccan, a young medtech company dedicated to improving the prognosis for patients diagnosed with pancreatic cancer. We are working to change the trajectory of pancreatic cancer mortality by finding the cancer at an earlier stage than today. We are developing an easy-to-use blood test for early detection of pancreatic cancer. The lack of diagnostic biomarkers and limitations with the gold standard tumour marker CA19-9 led the way to the exploration of tumour biology and biomarkers in pancreatic cancer tissue leading up to the founding of Reccan by clinicians and researchers at the Lund University Hospital.
